Introduction
Liposomes are spherical vesicles in which an aqueous volume is entirely enclosed by a membrane, composed of phospholipids. 1 Based on their special structural characteristics, it is possible to construct vesicles of various size in which certain molecules can be entrapped both within their aqueous compartment and within the membrane. This unique property enabled the utilization of liposomes as an immunoanalytical tool hosting various labels either in the internal aqueous cavity or the lipid bilayer, i.e. fluorescent molecules or enzymes. [2] [3] [4] [5] [6] [7] [8] Enzymes such as glucose oxidase, 9 alkaline phosphatase, 10 horseradish peroxidase (HRP) 3, 7, [11] [12] [13] [14] [15] and β-galactosidase, 16 have been applied as labels, either conjugated to the outside of the lipid bilayer of liposome or encapsulated into liposomes.
The preparation of enzyme-conjugated liposomes is a tedious and time-consuming procedure, while its encapsulation into the aqueous interior of liposomes is much more convenient.
HRP is widely used as a marker molecule in enzyme-immunoassays not only in research fields, but also in clinical diagnostics. Numerous commercial kits are based on antigen-HRP or antibody-HRP conjugates for the determination of various endogenous compounds, drugs, narcotics etc., especially with the utilization of chromogenic substrates. So far, the main strategy for increasing assay sensitivity was to replace HRP chromogenic substrates with fluorescent, or even better with chemiluminescent (CL) ones, or to increase the number of covalently attached HRP molecules per hapten conjugate. 17, 18 HRP catalyzes the reaction between a hydrogen acceptor (oxidant), such as hydrogen peroxide, and a hydrogen donor, such as luminol. The latter constitutes the most common CL substrate, and when oxidized emits light, following the decay of the excited-state oxidation product. The intensity of the emitted light can be greatly increased by adding in the substrate solution a molecule that works as an enhancer. 4-Iodophenol (4-IOP) 19 has emerged as the most popular enhancer of the HRP-catalyzed chemiluminescent oxidation of luminol. Enhanced chemiluminescent reactions provide more intense, prolonged and stable light emission. 20 A variety of substituted phenols have been applied as luminol signal enhancers, such as firefly luciferin, and 6-hydroxybenzothiazole derivatives, 21 along with arylboronic acid derivatives, e.g. 4-iodophenylboronic acid, 22 and even more complicated analogues. 23 In the current study, a novel approach for increasing the sensitivity of antigen-HRP conjugate based immunoassays was applied: Biotinylated anti-HRP antibody was utilized in order to attach, via a streptavidin bridge, liposomaly entrapped HRP.
The Lysis of the specifically bound liposomes released a large amount of HRP compounds, and adding the luminol/H2O2/ enhancer system led to a strong CL signal. Regarding a luminol enhancer, 4-(1-imidazolyl)phenol (4-IMP) was selected as the most potent one. 24 The new approach was applied in the case of fentanyl (MW 336.47), which was used as a model antigen, since there were data from previous assays developed in our laboratory. 17, 18, 24 A series of liposomes were prepared and tested for their % enzyme entrapment and their stability. The best combination was utilized to develop and validate a novel method for the determination of fentanyl in human plasma. Finally, the novel method was compared with a previously established method. To overcome the sensitivity limit for small molecules (haptens) in immunoassays based on antigen-horseradish peroxidase (HRP) conjugates as labels, a novel approach was established that afforded very low detection limits. Biotinylated anti-HRP antibody was utilized in order to attach, via a streptavidin bridge, liposomaly entrapped HRP. Fentanyl, used as a model antigen, could be determined via the generation of a high-intensity and relatively stable chemiluminescence (CL) signal of a HRP-catalyzed luminol/H2O2/enhancer system, immediately after the addition of a substrate solution. 4-(1-Imidazolyl)phenol (4-IMP) was used as an enhancer, and the outcome of this combination was a very low detection limit (0.895 pg mL -1 ) in plasma samples. The respective detection limit with the use of just the classical HRP-antigen conjugate was > 5-times higher. Intra-and inter-assay RSDs of the novel assay were 6.8 -9.9 and 11 -17%, respectively. The proposed method could be utilized for a wide range of molecules without replacing existing antigen-HRP based kits. 
Experimental

Reagents and chemicals
Fentanyl citrate ampules (50 μg mL -1 ) were kindly donated by Aretaieio Hospital (Athens, Greece). Anti-fentanyl rabbit polyclonal antibody (9.20 μM) was obtained from Biostride Inc. (USA). Fentanyl-HRP conjugate was obtained from USBIO (Europa Bioproducts, UK). Biotinylated anti-HRP rabbit polyclonal antibody (2.00 μM) was obtained from Dianova GmbH (Germany). Sulfo-NHS-LC-Biotin was obtained from Molecular Probes (Eugene, OR) and BSA (RIA and ELISA grade) was brought from Calbiochem (Germany). Tween 20 was purchased from ICN Biomedicals (Germany). Hydrogen peroxide (3%, w/v), 4-IMP, streptavidin, HRP type VI, luminol, tris(hydroxymethyl)aminomethane (Tris), cholesterol, Sephadex G-200, chloroform, methanol and all other reagents were obtained from Sigma-Aldrich (Athens, Greece). Phosphatidylcholine (PC), phosphatidylethanolamine (PE), dipalmitoylphosphatidylcholine (DPPC), dipalmitoyl phosphatidylethanolamine (DPPE), distearoylphosphatidylcholine (DSPC), N-biotinyl-phosphatidylethanolamine (N-BiPE) and N-biotinyl cap-phosphatidylethanolamine (N-Bi-CapPE) were purchased from Avanti Polar Lipids (Lab Supplies, Athens, Greece). All aqueous solutions and buffers were prepared using water deionized and doubly distilled (resistivity >18 MΩ cm). Human plasma was kindly donated from Ippokrateio hospital (Athens, Greece).
The washing solution used in this protocol was a PBS buffer (pH 7.40) without Tween 20, since the latter would cause earlier than needed liposomal lysis. The assay buffer was a washing solution containing 0.1% (w/v) BSA and 2% sodium salicylate as a displacing agent 25, 26 of fentanyl from plasma proteins. 27 Dilutions of conjugates and standards were made using the assay buffer. The coating buffer consisted of a 0.1 M carbonate/bicarbonate buffer (pH 9.60), and the blocking solution was a PBS buffer containing 1% (w/v) BSA. ) in Tris buffer (0.10 M) with a pH value of 8.50. Fentanyl solutions were kept in polypropylene tubes, due to its adsorption onto the glass surface.
Apparatus
All measurements were performed with a Fluostar Galaxy (BMG LabTechnologies GmbH, Germany) multifunctional microplate reader. Luminescence optics was installed for the experiments, and all emitting light was recorded without any emission filter. The 96-well microtiter plates (opaque white polystyrene plates with a Maxisorp surface, which exhibited low cross-talk between adjacent wells) were obtained from Nunc (Pnoi, Athens, Greece). All plates were washed with a fully automated Tecan Columbus (Tecan, Austria) 96-well microplate washer.
An extruder device with small pore (200 nm) polycarbonate filters, used for the stabilization of liposome size distribution, was obtained from Avestin Europe GmbH (Mannheim, Germany).
Liposome preparation and physicochemical characterization
Liposomes were prepared by the thin-film hydration method. 28 The lipid film was prepared by dissolving natural and non-natural lipids and cholesterol in a chloroform/methanol 3:1 mixture, and slowly evaporating the solvent in a flash evaporator. The compositions of the 9 liposomal preparations are presented in Table 1 . In all mixtures, a small portion of a biotinylated lipid was added (Fig. 1) . The film was left under vacuum for at least 2 h. The lipid film was hydrated in a HRP solution (3 mL, 50 U mL -1 in PBS) by slowly stirring for 1 h, in a water bath above the phase transition of the lipids (65 C). The resultant multilamellar vesicles (MLVs) were subjected to three freeze-thaw cycles, including extrusion via filters of the extruder device, interrupted by a 5 min resting period, in dry ice. The resultant suspension consisted of large unilamellar vesicles (LUVs) and non-entrapped HRP molecules. The latter was removed by gel filtration on a 1.5 cm × 25 cm Sephadex G-200 column preequilibrated with PBS (pH 7.40). Liposomes were eluted first, and the fractions were separated after measuring the CL intensity following the addition of luminol/H2O2/4-IMP substrate in a diluted liposomal solution (with PBS, 1:10000).
Size measurements were performed immediately after preparation of the liposomes as follows: a 50-μL liposome dispersion was 30-fold diluted in HPLC-grade water, and the average size of liposomes was measured. Samples were a. Mean value (n = 3) ± SD. b. Mean diameter (n = 3) ± SD. scattered, and a size distribution was obtained. The same procedure, in order to check stability, was repeated 10 days after preparation. HRP entrapment and liposomal stability was also examined for all 9 preparations for a 10-day period. The % HRP incorporation was determined from signal ratios corresponding to diluted (1:10000) liposomal to free HRP fractions. A 10-μL portion from these solutions was added into 96-well plates and treated exactly as described in the next paragraph (liposomal lysis, addition of CL substrate solution and measurement).
Immunoassay protocol
The protocol for chemiluminescence measurements is described in Fig. 2 . In brief, the wells of the microtiter plates were filled with 100 μL of fentanyl polyclonal antibody dilution (1:22000) in a coating buffer and incubated overnight at 4 C. Next, the antibody solution was removed and the plates were post-coated with 200 μL of the blocking solution for 1 h at room temperature. After being washed four times with 300 μL of a washing solution, the microwells were filled with 50 μL of fentanyl plasma standard solutions or plasma samples and 50 μL of the diluted (1:1200) fentanyl-HRP conjugate in an assay buffer, and incubated for 1 h at room temperature with gentle shaking. The wells were rewashed six times by means of the same washing solution; then, 100 μL of the diluted (1:5000) anti-HRP antibody in PBS was added and incubated for 30 min at room temperature with gentle shaking. After washing once again six times, wells were filled with 100 μL of a streptavidin solution (3 μg mL -1 ) in PBS and incubated for 15 min at room temperature. Another washing step with 6 replicates of 300 μL was followed by the addition of 100 μL of a diluted (1:50) liposomal solution obtained from gel filtration. Incubation lasted for 30 min, followed by a final washing step. Liposomal lysis was achieved by adding 50 μL of Tween-20 (0.1% v/v) in PBS and vortexing the plate for 10 min. CL development was carried out by adding 150 μL of a luminol substrate solution. The emitted light was measured immediately.
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Results and Discussion
Physicochemical characterization and stability of liposomes
The characterization of liposomes was initially conducted by estimating the % incorporation of HRP in the different preparations.
The incorporation efficiency of liposomal preparations is summarized in Table 1 . From this table it can be concluded that when synthetic lipids were utilized, the % incorporation of HRP is increased, compared to liposomes composed of natural lipids. Overall, the % incorporation of HRP was low, but this outcome can be attributed to the bulky size of the enzyme. The same table shows that the presence of DPPE lipid led to a decreased incorporation of HRP. The biotinylated lipid with the larger chain (N-Bi-CapPE) seems to enhance enzyme entrapment. However, a bigger ratio of this lipid decreased the incorporated HRP, probably due to destabilization of the lipid layer. The same table contains data for the size of all liposomal preparations.
In terms of stability, all liposomal preparations were monitored for a period of 10 days. Specifically, in order to estimate the stability of liposomes under storage in solution at 4 C, aliquots were sampled at 0, 1, 2, 5, 7 and 10 days, respectively. Figure 3 shows the evolution of % HRP entrapment lipids after the purification of liposomes sampled by gel filtration through Sephadex G-200. Based on data from Table 1 and Fig. 3 , it can be concluded that the G mixture combined both a higher % HRP entrapment value and a more stable performance, and therefore it was the one utilized as a marker of the immunoassay. It should be emphasized that an increased release rate of HRP was combined with aggregation phenomena that occurred with the formation of precipitates, while the increase in the mean diameter was also monitored. As far as the liposomal preparation based on the G mixture is concerned, these phenomena started appearing after 7 days, which means that the suggested marker can be used for the same period.
Calibration curve and detection limit
The obtained signals of the fentanyl plasma standard solutions, for the novel liposome immunoassay, were fitted by means of the 4-parameter logistic equation 29 (Fig. 4) . The standard curves were plotted as mean B/Bo against the logarithm of the antigen concentration, where B/Bo was the obtained signal divided by Table 2 presents data for the mean calibration curve, which were obtained via GraphPad Prism v5 Trial software.
The minimum detectable concentration was defined as the concentration of fentanyl corresponding to the signal of the zero plasma standard minus three standard deviations of the same zero standard. The detection limit was calculated to be 0.895 pg mL -1 , which is lower than that achieved with the same substrate in a non-liposome immunoassay for fentanyl, using the same polyclonal antibody. 18 This decrease can be attributed to the entrapment of many HRP molecules in the liposomal cavity.
Precision and accuracy
Intra-and inter-assay %RSD values ranged from 6.8 to 9.9 and 11 to 17%, respectively ( Table 3 ). The relative high %RSD values can be attributed to the increased number of steps during the assay procedure, and since each step has its own standard deviation (SD), the total SD becomes
The accuracy was evaluated by adding increasing amounts of fentanyl to plasma samples, and measuring the percentage recovery. The mean percentage recovery values ranged from 91.6 to 116%, and were not significantly affected by the dose (Table 3) .
Dilution linearity
Dilution linearity was assessed by serially diluting 6 plasma samples with a relatively high fentanyl concentration 2 -16-fold with zero standard samples and assayed as unknown. The results were plotted as a least-squares linear regression of the expected concentration versus the observed concentration, giving very satisfactory linearity (R > 0.991) and accuracy data.
Cross reactivity
The selectivity of the assay was tested by testing three other available synthetic opioids (sufentanil, alfentanil and remifentanil) that could act as cross-reactants. The cross reactivity was calculated by using the 50% displacement method (which corresponds to a 50% signal decrease). This includes the preparation of displacement curves after the incubation of increasing doses of the possible cross-reactant for 1 h. In other words, the previously described protocol was again applied, but instead of adding fentanyl calibrators, solutions with increasing concentrations (1.00 -10.0 × 10 6 pg mL -1 ) of these synthetic opioids were added. Fitting of the curves was conducted by a 4-parameter logistic model, and the concentrations of the cross-reactant were estimated at 50% signal displacement. Both assays indicated 100% cross reactivity for fentanyl and < 0.01% for sufentanil, alfentanil and remifentanil.
Comparison of the novel approach with existing antigen-HRP based kits
In order to compare the novel assay with the existing antigen-HRP based kit, 20 spiked samples (ranging from 1.50 till 500 pg mL -1 ) were tested by both methods. A best-fit line was inserted through the data points, and the slope and Y intercept were calculated. The following equation was obtained:
where C1 and C2 correspond to the kit assay and the liposome assay data, respectively. The correlation coefficient was 0.998, while statistical data for the slope and intercept are presented in Table 4 (obtained from SPSS v16 software). There, it can be monitored, since p-value (0.00) for slope is less than the significance level (0.05), that the null hypothesis (slope = 0) is rejected and there is no proportional error in the novel method. Similarly, since the p-value (0.363) for the intercept is higher than the significance level (0.05), the null hypothesis is accepted, and therefore there is no evidence for a constant error in the liposome immunoassay.
Perspective
The use of a liposome immunoassay with entrapped HRP as a label, in combination with a chemiluminescent substrate, resulted in a very sensitive method. In this case, a >5 times decrease in the detection limit was achieved (0.895 pg mL -1 ) compared to the classical HRP-fentanyl based assay (5.12 pg mL -1 ), by using the same CL substrate solution. This result is significant, and overcomes the multiple addition and washing steps. Perhaps, it is not the method of choice for routine work in a clinical laboratory, but it can be applied to most cases, when insufficient sensitivity is achieved with classical kits. No replacement of existing reagents is needed, just the addition of a diluted biotinylated anti-HRP antibody solution. Considering the difficulty in preparing liposomes, an alternative option to increase the sensitivity in a classical HRP-antigen based kit is to replace the label by adding a diluted solution of streptavidin-HRP conjugate, 17, 18 thus solving simultaneously all stability problems.
Conclusions
A novel immunoassay approach was presented, which enhances the performance of an antigen-HRP based kit. The addition of a biotinylated anti-HRP antibody is the key step for the attachment, via a streptavidin bridge, of a novel liposomal tracer along with a chemiluminescent substrate of HRP. Regarding the model-antigen fentanyl, this assay was validated, and was shown to have the lowest detection limit (0.895 pg mL -1 ), compared to other previously developed protocols. This approach, even with variations regarding the tracer, has the potential to be applied to increase the sensitivity of classical HRP-based kits. 
